39 studies found for:    apatinib
Show Display Options
Rank Status Study
1 Recruiting Apatinib for Metastatic Esophageal Cancer.
Conditions: Esophageal Cancer;   Metastatic Esophageal Cancer;   Apatinib
Intervention: Drug: Apatinib
2 Active, not recruiting The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
Condition: Stomach Neoplasms
Interventions: Biological: Cytokine-Induced Killer Cells;   Drug: Apatinib
3 Active, not recruiting The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR
Condition: Adenocarcinoma of Lung
Interventions: Biological: Cytokine-Induced Killer Cells;   Drug: Apatinib
4 Recruiting Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Apatinib single agent arm
5 Recruiting The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: apatinib single agent
6 Recruiting Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma
Condition: Esophageal Squamous Cell Carcinoma
Interventions: Drug: Apatinib;   Drug: Irinotecan
7 Recruiting Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer
Condition: Gastric Cancer
Intervention: Drug: apatinib
8 Recruiting Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy
Conditions: Osteosarcoma;   Metastasis
Intervention: Drug: apatinib
9 Completed A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
Condition: Non-Small-Cell Lung Cancer
Interventions: Drug: apatinib;   Drug: placebo
10 Not yet recruiting Apatinib as Second-line Treatment of Advanced Pancreatic Cancer
Condition: Pancreatic Neoplasms
Intervention: Drug: Apatinib
11 Recruiting Study of Apatinib in Metastatic Esophageal Cancer
Condition: Esophageal Cancer
Intervention: Drug: Apatinib
12 Recruiting The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Apatinib;   Drug: Etoposide
13 Completed A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: Apatinib
14 Not yet recruiting Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study
Conditions: Hepatocellular Carcinoma;   Pulmonary Metastasis
Interventions: Drug: Apatinib;   Procedure: TACE
15 Recruiting A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients
Condition: Hepatocellular Carcinoma
Intervention: Drug: Apatinib
16 Not yet recruiting Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR
Condition: Lung Adenocarcinoma
Interventions: Drug: Apatinib (250 mg/d) + Docetaxel (60 mg/m2);   Drug: Apatinib (500 mg/d) + Docetaxel (60 mg/m2);   Drug: Apatinib (750 mg/d) + Docetaxel (60 mg/m2)
17 Recruiting Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Apatinib;   Drug: Placebo
18 Completed Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients
Condition: Metastatic Breast Cancer
Intervention: Drug: Apatinib
19 Recruiting A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer
Condition: Gastric Carcinoma
Interventions: Drug: Docetaxel;   Drug: apatinib
20 Completed A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma
Condition: Advanced Hepatocellular Carcinoma
Intervention: Drug: Apatinib

   Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results    Last Page
Indicates status has not been verified in more than two years